Medifron DBT Co. Ltd (065650) — Cash Flow-to-Debt Ratio
Medifron DBT Co. Ltd (065650) has a Cash Flow-to-Debt Ratio of -0.15x as of September 2025, meaning its operating cash flow of ₩-12.73 Billion could theoretically repay 0% of its total liabilities (₩86.61 Billion) in one year. See free cash flow generation of Medifron DBT Co. Ltd to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Medifron DBT Co. Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Medifron DBT Co. Ltd across 11 annual periods. Also explore how fast is Medifron DBT Co. Ltd growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Medifron DBT Co. Ltd (2014–2024)
Year-by-year debt coverage analysis for Medifron DBT Co. Ltd. For market capitalisation and broader financial context, see Medifron DBT Co. Ltd market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.11x | ₩-4.54 Billion | ₩42.92 Billion | ▲ +6.6% |
| 2023 | -0.11x | ₩-2.14 Billion | ₩18.89 Billion | ▲ +4.2% |
| 2022 | -0.12x | ₩-2.91 Billion | ₩24.66 Billion | ▲ +46.5% |
| 2021 | -0.22x | ₩-1.50 Billion | ₩6.81 Billion | ▼ -155.3% |
| 2020 | -0.09x | ₩-1.67 Billion | ₩19.36 Billion | ▲ +96.4% |
| 2019 | -2.42x | ₩-4.28 Billion | ₩1.77 Billion | ▼ -574.2% |
| 2018 | -0.36x | ₩-852.48 Million | ₩2.37 Billion | ▲ +54.2% |
| 2017 | -0.78x | ₩-1.17 Billion | ₩1.49 Billion | ▼ -48.2% |
| 2016 | -0.53x | ₩-1.15 Billion | ₩2.18 Billion | ▼ -2085.2% |
| 2015 | -0.02x | ₩-170.27 Million | ₩7.04 Billion | ▼ -5408.5% |
| 2014 | 0.00x | ₩701.96K | ₩1.54 Billion | — |